Searching for novel MDM2/MDMX dual inhibitors through a drug repurposing approach
Disruption of p53-MDM2/MDMX interaction by smaller inhibitors is a promising therapeutic intervention gaining tremendous interest. However, no MDM2/MDMX inhibitors have been marketed so far. Drug repurposing is a validated, practical approach to drug discovery. In this regard, we employed structure-...
Saved in:
Main Authors: | Keting Li, Wenshu Hu, Yingjie Wang, Wenxing Chen, Hongmei Wen, Jian Liu, Wei Li, Bo Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/14756366.2023.2288810 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ezetimibe Anticancer Activity via the p53/Mdm2 Pathway
by: Charmy Twala, et al.
Published: (2025-01-01) -
Small-molecule MMRi36 induces apoptosis in p53-mutant lymphomas by targeting MDM2/MDM4/XIAP for degradation
by: Rati Lama, et al.
Published: (2024-12-01) -
Novel Inhibitors for MDM2-MDM4 E3 Ligase Potently Induce p53-Indepedent Apoptosis in Drug-Resistant Leukemic Cells
by: Rati Lama, et al.
Published: (2025-01-01) -
Dual EMCV-IRES-integrated dengue virus can express an exogenous gene and cellular Mdm2 integration suppresses the dengue viral replication
by: Tadahisa Teramoto
Published: (2025-01-01) -
CENPN contributes to pancreatic carcinoma progression through the MDM2-mediated p53 signaling pathway
by: Ming Xu, et al.
Published: (2024-04-01)